Our study indicated that sorafenib had no significant effect on the expression of AFP in HCC cells, suggesting that the decrease in the serum AFP level in HCC patients was most likely due to the regression of HCC tumors after sorafenib intervention. This evidence concerns the gene AFP and hepatocellular carcinoma.